What is Nucala®?
Nucala® (generic name: mepolizumab) is a type of monoclonal antibody injection that targets a protein called interleukin-5 (IL-5). IL-5 plays an important role in the growth and survival of eosinophils – a type of white blood cell involved in allergic inflammation and asthma.
By blocking IL-5, Nucala helps reduce eosinophil counts in the blood and tissues. This lowers inflammation and improves symptoms in several eosinophil-related conditions.
Approved Uses of Nucala®
Nucala® has been approved by the FDA/EMA for the following conditions:
- Severe Eosinophilic Asthma
- For patients with high eosinophil counts (≥150 cells/µL).
- Used as an add-on treatment when inhaled corticosteroids and long-acting bronchodilators are not enough.
- Helps reduce asthma attacks, hospital visits, and the need for oral steroids.
- Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- A rare blood vessel inflammation linked to eosinophils.
- Used with glucocorticoids to help bring the disease under control and reduce relapses.
- Reduces long-term dependence on steroids.
- Hypereosinophilic Syndrome (HES)
- A condition with abnormally high eosinophil levels causing organ damage.
- Approved for patients 12 years and older with no clear underlying cause.
- Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
- For adults 18 years and older who cannot control symptoms with standard treatments like nasal steroids.
- Helps reduce nasal congestion, polyp size, and the need for surgery.
How Does Nucala® Work?
- Nucala® belongs to the IgG1 kappa monoclonal antibody class.
- It works by blocking IL-5 signaling, which reduces eosinophil production, recruitment, and survival.
- This decreases airway and tissue inflammation, improving breathing and symptoms
How is Nucala® Given?
- Subcutaneous injection (under the skin).
- Available in pre-filled syringes or autoinjectors.
Typical doses:
- Severe eosinophilic asthma: 100 mg every 4 weeks
- EGPA: 300 mg every 4 weeks
- HES: 300 mg every 4 weeks
- CRSwNP: 100 mg every 4 weeks
- First doses are usually given at a hospital or clinic.
- Some patients may later be trained to inject at home safely.
Possible Side Effects
Common side effects:
- Headache
- Injection site reactions (swelling, redness, pain)
- Back or joint pain
- Fatigue
Less common but important:
- Severe allergic reaction (anaphylaxis)
- Shingles infection (herpes zoster)
- Delayed allergic reactions
If you experience rapid hives, facial swelling, chest tightness, wheezing, dizziness, or fainting after injection, seek emergency care immediately.
Safety Precautions
- Nucala® is not an emergency medication. It cannot replace inhalers, rescue bronchodilators, or epinephrine.
- First injections should be given in a medical setting for observation.
- Patients should keep up-to-date with vaccines, especially shingles vaccine, if recommended by the doctor.
- Do not stop your regular inhalers or steroids without medical advice.
Frequently Asked Questions (FAQ)
Q: Can children use Nucala®?
A: Yes, for severe eosinophilic asthma in patients 6 years and older. For EGPA, HES, and CRSwNP, use is generally approved for 12–18 years and older, depending on the condition.
Q: How long do I need to take Nucala®?
A: Nucala® is usually a long-term treatment. Doctors reassess symptoms every 4–6 months to decide whether to continue.
Q: Is Nucala® expensive?
A: Yes. It is a biologic medication, which tends to be costly. Cost varies by country, dose, and insurance coverage.
Q: What tests are needed before starting Nucala®?
A: A blood test for eosinophil levels is usually required.
Key Takeaway
Nucala® (Mepolizumab) is an advanced treatment for patients with severe eosinophilic asthma, EGPA, HES, and nasal polyps. It works by lowering eosinophil levels and reducing inflammation.
It is effective in decreasing symptoms and steroid use, but it is not a rescue medication. Always use Nucala® under the supervision of a specialist.
